Recently, a study reported that patients with CDH12-enriched bladder cancers have poor outcome of neoadjuvant chemotherapy, and that CDH12-enriched cancer cells exhibit aggressiveness and chemoresistance47. The gene discussed is CDH12; the disease is urinary bladder cancer.